Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Mar;40(2):95-96.
doi: 10.3343/alm.2020.40.2.95.

Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine

Soo Youn Lee  1   2
Affiliations
Editorial

Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine

Soo Youn Lee. Ann Lab Med. 2020 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this paper were reported.

Comment on

References

    1. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685–698. - PubMed
    1. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835–857. - PubMed
    1. Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med. 2017;37:97–107. - PMC - PubMed
    1. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–1668. - PMC - PubMed
    1. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019;15:837–848. - PubMed

Substances

LinkOut - more resources